Paclitaxel Delivery to the Brain for Glioblastoma Treatment

Muhammad AbdEl-haq, Awanish Kumar, Fatima Ezzahra Ait Mohand, Nataly Kravchenko-Balasha, Yakir Rottenberg, Abraham J. Domb*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


The development of paclitaxel-loaded polymeric nanoparticles for the treatment of brain tumors was investigated. Poly(lactide-glycolide) (PLGA) nanoparticles containing 10% w/w paclitaxel with a particle size of 216 nm were administered through intranasal and intravenous routes to male Sprague–Dawley rats at a dose of 5 mg/kg. Both routes of administration showed appreciable accumulation of paclitaxel in brain tissue, liver, and kidney without any sign of toxicity. The anti-proliferative effect of the nanoparticles on glioblastoma tumor cells was comparable to that of free paclitaxel.

Original languageAmerican English
Article number11722
JournalInternational Journal of Molecular Sciences
Issue number14
StatePublished - 21 Jul 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.


  • brain delivery
  • glioblastoma treatment
  • intranasal (IN)
  • intravenous (IV)
  • nanoparticles (NPs)
  • paclitaxel (PTX)
  • poly(lactic-co-glycolic acid) (PLGA)


Dive into the research topics of 'Paclitaxel Delivery to the Brain for Glioblastoma Treatment'. Together they form a unique fingerprint.

Cite this